Innate immune cells such as natural killer (NK) cells play a crucial role in antitumor immune responses. NKG2D is a major activating immunoreceptor expressed in not only NK cells but also CD8
Introduction
Recent studies have indicated that innate and adaptive immune systems mediated by natural killer (NK)/cytotoxic T cells are involved in mechanisms of surveillance for tumor elimination. 1, 2 
NKG2D is a C-type lectin-like activating receptor and is expressed in various immune cells, including NK cells, natural killer T-cells (NKT), CD8
þ a/b T cells, and g/d T cells. 3, 4 Human NKG2D recognizes two families of unusual major histocompatibility complex (MHC) class I molecules, the family of MHC class I-related chain genes, including MICA and MICB, and the UL-16-binding protein family. 5, 6 These NKG2D ligands are almost undetectable in a stable state and in normal tissue but are induced on the cell surface by various stresses such as heat shock, cell transformation and viral infection.
3,7-9 NKG2D ligands are expressed in many malignant cells such as those in colon, 10 liver, 11 ovary 12 and hematological malignancies. 7, [13] [14] [15] [16] It has also been suggested that involvement of NKG2D in NK cell-mediated cytotoxicity strictly correlates with the expression levels and surface densities of its ligands on target cells. 7 Moreover, it has been demonstrated that a high level of MICA expression is associated with a good prognosis in colorectal cancer patients. 10 NKG2D and its ligands have recently been shown to be an important immune pathway for antitumor surveillance. 17 However, it has been reported that tumors try to slip through this surveillance system by escaping from recognition of immunocompetent cells through change in the expression of their ligands for NK receptors. 18, 19 Thus, it is possible that the antitumor effect of immunocompetent cells is enhanced by increasing recognition of tumor cells via enhanced expression levels of NK-activating ligands.
Chromatin remodeling through histone acetylation is one of the major mechanisms of transcriptional control of genes 20 and is involved in 'gene silencing' of antioncogenes in various tumor cells, and these inhibitors are potent inducers of growth arrest, differentiation and apoptosis of tumor cells. [21] [22] [23] Moreover, chromatin remodeling is involved in transcriptional control of some genes such as NKG2D ligands, 11 Ly49a and killer cellimmunoglobulin-like receptor. 24, 25 The effectiveness of chromatin-remodeling drugs such as the histone deacetylase (HDAC) inhibitor sodium N-butyrate, suberoyl anilide hydroxamic acid (SAHA) 26 and depsipeptide (FK228) 27, 28 against many tumors, including hematological malignancies, has been demonstrated in vivo and in vitro.
In this study, we were able to increase the expression levels of MICA and MICB on leukemic cells using a chromatinremodeling drug, and we analyzed the effect of upregulated NKG2D ligands on the susceptibility of leukemic cells, including primary leukemic cells derived from patients, to the cytotoxicity of NKG2D-expressing cells.
Materials and methods

Cells and culture conditions
BALL1, Jurkat (lymphoid leukemia) and K562 (myeloid leukemia) cells were obtained from Riken (Tsukuba, Japan). Peripheral blood or bone marrow cells were collected from eight leukemia patients at the time of diagnosis, including two patients with lymphoblastic lymphoma, two patients with Ph acute lymphocytic leukemia (ALL), one patient with follicular lymphoma, one patient with T-ALL, one patient with B-ALL and one patient with adult T-cell leukemia (Table 1) , and from four healthy donors. Informed consent for the analysis of blood cells was obtained from all patients. Cells were maintained in RPMI1640 medium supplemented with 10% (v/v) fetal calf serum. ) were cultured with immobilized anti-CD3 mAb (OKT3, 1 mg/ml, Ortho Biotech, Raritan, NJ, USA) and interleukin (IL)-15 (5 ng/ml, R&D Systems) in RPMI1640 medium for 7 days, as reported previously. 29, 30 Then cytolytic effector cells that expressed NKG2D more than 90% were purified by magnetic cell sorting using magnetic microbeads (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). These expanded NKG2D-expressing cell also express inhibitory NK receptors (CD94/NKG2A). The cytotoxicity against 51 Crlabeled human leukemic cells and autologous phytohemagglutinin (PHA) blasts (5 Â 10 3 ) without prior sensitization was tested. Patients' cells were preincubated in the presence or absence of TsA (200-400 nM) for 12 h.
Monoclonal antibodies and reagents
Real-time PCR, flow cytometry, chromatin immunoprecipitation assay
Relative quantification assays for gene expression were performed using an Applied Biosystems 7300 Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). Fluorescence intensity of the cells incubated with the specific antibodies was analyzed using an FACS Calibur (Becton Dickinson, San Jose, CA, USA). Chromatin immunoprecipitation (ChIP) assay was performed as described previously. 31 The immunoprecipitated DNA was subsequently analyzed by PCR with primers specific to the MICA or MICB promoter region. PCR products were separated on 2% agarose gels and then stained with ethidium bromide and quantified by Scion image.
Results
HDCA inhibitors induce MICA and MICB expression in BALL1, Jurkat and K562 cells
In order to determine whether MICA and MICB expression is associated with histone acetylation in leukemic cells, we tested the effect of TsA and SB treatment for 12 h on BALL1, Jurkat and K562 cells and examined the alteration of MICA and MICB mRNA expression using real-time PCR. Treatment of BALL1 cells with TsA significantly increased MICA and MICB mRNA expression by more than twofold (Table 2A) . We next examined the expression levels of MICA and MICB proteins on the cell surface in the presence or absence of TsA using flow cytometry analysis. Treatment of BALL1 cells with TsA significantly increased MICA and MICB protein expression levels (Table 2B) . We analyzed MICA/B mRNA and protein levels following treatment with TsA and also SB using not only BALL1 cells but also another lymphoid leukemic cell line, Jurkat, and a myeloid cell line, K562. Treatment with HDAC inhibitors, TsA and SB, resulted in upregulation of MICA and MICB mRNA and Abbreviations: ALL, acute lymphocytic leukemia; BMT, bone marrow transplantation; CHx, chemotherapy; F, female; FL, follicular lymphoma; HLA, human leukocyte antigen; LBL, lymphoblastic lymphoma; M, male; MFI, mean fluorescence intensity; MICA, major histocompatibility complex class I-related chain A; MICB, major histocompatibility complex class I-related chain B; PBMC, peripheral blood mononuclear cells; PBSCT, peripheral blood stem cell transplantation; Ph ALL, Ph acute lymphocytic leukemia; Pt., patient. (Figure 1 ). MICA and MICB protein expression levels on the cell surface were also increased (Table 1) . Intriguingly, elevation of MICA and MICB expression levels following TsA treatment was not observed in mononuclear cells from four healthy donors, suggesting that TsA does not have a significant effect on MICA and MICB expression in normal cells.
Treatment with TsA resulted in increased acetylation of histone H3 and decreased association with HDAC1 at the promoters of MICA and MICB in leukemic cells
To determine whether upregulation of MICA and MICB expression by TsA treatment is associated with histone acetylation of their promoter regions, we performed ChIP assays using anti-acetylated histone H3 mAb in BALL1 cells and also Upregulated MICA and MICB expression following TsA treatment enhances the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells
To determine the effect of treatment with TsA on the cytotoxicity of NKG2D-expressing cells against leukemic cells, we performed 51 Cr release assays using NKG2D-expressing cells that had been expanded by a previously reported method. 29, 30 Since these expanded NKG2D-expressing cells also express inhibitory NK receptors (CD94/NKG2A), their cytotoxicity roughly depend on the expression of human leukocyte antigen (HLA) class I molecules on the cell surface in inverse proportion and they cannot attack BALL1 cells and lymphoid leukemic cells with high expression level of HLA class I. 29, 30 Therefore, we tried to estimate the susceptibility of lymphoid leukemic cells that were protected by HLA class I to the cytotoxicity of these NKG2D-expressing cells before and after TsA treatment. The cytotoxicities of NKG2D-expressing cells against BALL1 cells and also most of the patients' lymphoid leukemic cells were enhanced after treatment with TsA (Figure 3a) . Patients' lymphoid leukemic cells usually express a high level of HLA class I molecules before TsA treatment, but the patients' lymphoid leukemic cells expressed a high level of MICA/B after TsA treatment (Table 1) . Therefore, the susceptibility of lymphoid leukemic cells to the cytotoxicity of NKG2D-expressing cells could be upregulated. In addition, to examine the effect of TsA on the function of NKG2D-expressing cells, TsA was added to the medium during 51 Cr release assays for 4 h, but it was found that TsA had no effect on the cytotoxicity (data not shown). To determine whether this upregulated cytotoxicity was critically dependent on NKG2D, MICA and MICB expression, we next performed a blocking experiment using specific antibodies. Anti-NKG2D mAb significantly inhibited the cytotoxicity against BALL1 cells, and anti-MICA and anti-MICB mAbs at least partly inhibited the cytotoxicity (Figure 3b) . These results suggested that the cytotoxicity of NKG2D-expressing cells was regulated by the expression of NKG2D and its ligands. However, this cytotoxicity was not regulated by only one ligand but by a combination of several activating ligands.
Discussion
In this study, we found that MICA and MICB expression was at least partly regulated by chromatin remodeling. The acetylation status of histones at the gene promoter is a marker of transcriptional activity of the gene. Hypoacetylation of histones by HDACs at the promoter region indicates transcriptional Figure 2 Levels of acetylated histone H3 and associated HDAC1 at the MICA and MICB promoters in BALL1 cells and patients' leukemic cells after treatment with TsA. ChIP assays were performed with antiacetyl histone H3 mAb or anti-HDAC1 mAb, and immunoprecipitated DNA was subjected to PCR with primers specific to the MICA or MICB promoter. ChIP PCR products were separated on 2% agarose gels and stained with ethidium bromide. Ten percent of the cell lysate was used as input. BALL1 cells were treated with TsA for indicated times. ChIP, chromatin immunoprecipitation; HDAC, histone deacetylase; mAb, monoclonal antibody; MICA, major histocompatibility complex class I-related chain A; MICB, major histocompatibility complex class I-related chain B; TsA, trichostatin A. 32, 33 TsA is a hydroxamic acid derivative that chelates zinc irons present in the active sites of an enzyme and inhibits HDACs. Our present results clearly demonstrated that treatment with TsA induced MICA and MICB mRNA and protein expression in BALL1 cells and patients' primary leukemic cells. We also found that SB, another HDAC inhibitor, has the same effects on MICA mRNA and protein expression in other leukemic cell lines such as Jurkat and K562 cells. Therefore, this phenomenon applies to both lymphoid leukemia and myeloid leukemia and also applies to other HDAC inhibitors such as SB. Furthermore, Armeanu et al. 11 reported that the HDAC inhibitor sodium valproate (VPA) induced the expression of MICA and MICB in hepatocellular carcinoma. These results suggest that the expression of NKG2D ligands was at least partly regulated by histone acetylation.
HDAC inhibitors are cytotoxic against tumor cells, but, fortunately, normal cells appear to be resistant to HDAC inhibitors. 34 Armeanu et al. 11 reported that MICA and MICB expression levels were not elevated following VPA treatment in non-malignant primary human hepatocytes from healthy donors. Our results also showed that treatment with TsA did not increase MICA and MICB expression levels in mononuclear cells from healthy donors. These results suggest that the expression of NKG2D ligands on normal cells is strictly regulated and that normal cells are not killed by auto-NKG2D-expressing cells.
ChIP assays showed that histones associated with the promoters of MICA and MICB in untreated leukemic cells were hypoacetylated by HDAC and were acetylated by treatment with TsA, leading to transcriptional activation. HDAC1 regulates gene transcription not only through deacetylation of core histones but also through deacetylation of various transcription factors. 30 Our study demonstrated that treatment with TsA was involved in facilitated dissociation of HDAC1 from MICA and MICB promoters. It appeared that HDAC1 was responsible for deacetylation of histones at MICA and MICB promoters.
We also demonstrated that the expression of activating ligands for NKG2D on leukemic cells could be induced by chromatin-remodeling drugs, leading to enhancement of the susceptibility of BALL1 cells and patients' primary leukemic cells to the cytotoxicity of NKG2D-expressing cells. Indeed, patients leukemic cells (Pt7 and Pt8) in which treatment with TsA resulted in increased acetylation of histone H3 and decreased association with HDAC1 at the promoters of MICA and MICB showed a more than fourfold increase of susceptibility to the cytotoxicity of NKG2D-expressing cells.
This cytotoxicity was obviously dependent on interaction with NKG2D and its ligands, because the cytotoxicity of NKG2D-expressing cells was blocked by an anti-NKG2D mAb. However, the cytotoxicity of NKG2D-expressing cells was not inhibited by only a single mAb for MICA or MICB. These results suggest that the cytotoxicity of NKG2D-expressing cells is upregulated by the sum total of expression of its activating ligands on target cells. Also, these cells express inhibitory NK receptors (CD94/NKG2A), and their cytotoxicity is therefore downregulated by the sum total of their inhibitory ligands such as HLA class I molecules. These many activating and inhibitory ligands on target cells might make the susceptibility of patients' leukemic cells to the cytotoxicity of NKG2D-expressing cells difficult to estimate from only MICA/B expression on leukemic cells.
Recent studies have shown that MICA is released as a soluble form from the cell surface due to the activity of metalloproteinases and that soluble MICA (sMICA) is associated with downregulated NKG2D expression and impaired activation of NK cells. [35] [36] [37] [38] Therefore, this issue should be considered to evaluate the clinical relevance of induction of NKG2D ligands using chromatin-remodeling drugs.
In the present study, we demonstrated that chromatin remodeling was involved in the expression of NKG2D ligands of not only leukemic cell lines but also primary leukemic cells from patients. Our data suggested that enhancement of the expression of NKG2D ligands using chromatin-remodeling drugs may be an attractive therapeutic strategy to induce susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells.
